Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

7K41

Bacterial O-GlcNAcase (OGA) with compound

7K41 の概要
エントリーDOI10.2210/pdb7k41/pdb
分子名称O-GlcNAcase BT_4395, ACETATE ION, 4-(4-methylpiperidin-1-yl)-N-(2-phenylethyl)pyrimidin-2-amine, ... (5 entities in total)
機能のキーワードoga, virtual screening, structure based drug design, sbdd, transferase, transferase-transferase inhibitor complex, transferase/transferase inhibitor
由来する生物種Escherichia coli K-12
タンパク質・核酸の鎖数1
化学式量合計83552.48
構造登録者
Lane, W.,Tjhen, R.,Snell, G.,Sang, B. (登録日: 2020-09-14, 公開日: 2021-01-13, 最終更新日: 2023-10-18)
主引用文献Tawada, M.,Fushimi, M.,Masuda, K.,Sun, H.,Uchiyama, N.,Kosugi, Y.,Lane, W.,Tjhen, R.,Endo, S.,Koike, T.
Discovery of a Novel and Brain-Penetrant O -GlcNAcase Inhibitor via Virtual Screening, Structure-Based Analysis, and Rational Lead Optimization.
J.Med.Chem., 64:1103-1115, 2021
Cited by
PubMed Abstract: -GlcNAcase (OGA) has received increasing attention as an attractive therapeutic target for tau-mediated neurodegenerative disorders; however, its role in these pathologies remains unclear. Therefore, potent chemical tools with favorable pharmacokinetic profiles are desirable to characterize this enzyme. Herein, we report the discovery of a potent and novel OGA inhibitor, compound , comprising an aminopyrimidine scaffold, identified by virtual screening based on multiple methodologies combining structure-based and ligand-based approaches, followed by sequential optimization with a focus on ligand lipophilicity efficiency. This compound was observed to increase the level of -GlcNAcylated protein in cells and display suitable pharmacokinetic properties and brain permeability. Crystallographic analysis revealed that the chemical series bind to OGA via characteristic hydrophobic interactions, which resulted in a high affinity for OGA with moderate lipophilicity. Compound could serve as a useful chemical probe to help establish a proof-of-concept of OGA inhibition as a therapeutic target for the treatment of tauopathies.
PubMed: 33404239
DOI: 10.1021/acs.jmedchem.0c01712
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (2 Å)
構造検証レポート
Validation report summary of 7k41
検証レポート(詳細版)ダウンロードをダウンロード

248636

件を2026-02-04に公開中

PDB statisticsPDBj update infoContact PDBjnumon